EUVIMEDEUVIMED entdecken
Crossref

Real-World Outcomes of Neoadjuvant Pembrolizumab plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer: A Multicenter Study from Türkiye

Rashad Ismayilov, Arzu Oğuz, Arif Akyıldız, Engin Hendem, Elvina Almuradova, Özden Altundağ, Kadri Altundağ

Eurasian Journal of Medical Investigation · 2026 · 171-178

DOI: 10.14744/ejmi.266171 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Eurasian Journal of Medical Investigation, 2026. Verfasst von Rashad Ismayilov und 6 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Neoadjuvant pembrolizumab plus chemotherapy is the standard of care for high-risk early-stage triple-negative breast cancer (eTNBC), yet real-world data remain limited. We evaluated the effectiveness and safety of this regimen in Türkiye.

Methods

This multicenter retrospective cohort study included consecutive adults with stage I–III eTNBC treated with neoadjuvant pembrolizumab plus chemotherapy between 2022 and 2025 at four centers. Primary endpoints were pathological complete response (pCR) and event-free survival (EFS). Safety was assessed using CTCAE v5.0 criteria.

Results

Sixty-one women were included (median age 44 years); 37.7% had stage III disease and 62.3% had nodal involvement. Most tumors were grade 3 (78.7%) with high Ki-67 (>=40% in 85.2%). Planned neoadjuvant chemotherapy was completed in 91.8% of patients. The pCR rate was 62.3%. At a median follow-up of 12.2 months, five EFS events (8.2%) occurred. Estimated 12-and 18-month EFS rates were 91.4% and 86.8%. pCR was the only significant predictor of EFS (1-year EFS 100% vs. 75.5%, p = 0.001). Grade >=3 adverse events were mainly hematologic, while severe immune-related toxicity was rare.

Conclusion

Neoadjuvant pembrolizumab plus chemotherapy demonstrated high pCR rates and preliminary favorable early survival outcomes in real-world practice, confirming pathological response as a key driver of prognosis in eTNBC.

Zitieren

APA

Ismayilov, R., Oğuz, A., Akyıldız, A., Hendem, E., Almuradova, E., Altundağ, Ö., & Altundağ, K. (2026). Real-World Outcomes of Neoadjuvant Pembrolizumab plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer: A Multicenter Study from Türkiye. Eurasian Journal of Medical Investigation, 171-178. https://doi.org/10.14744/ejmi.266171

Vancouver

Ismayilov R, Oğuz A, Akyıldız A, Hendem E, Almuradova E, Altundağ Ö, et al. Real-World Outcomes of Neoadjuvant Pembrolizumab plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer: A Multicenter Study from Türkiye. Eurasian Journal of Medical Investigation. 2026:171-178. doi:10.14744/ejmi.266171

BibTeX
@article{Ismayilov2026,
  author = {Ismayilov, Rashad and Oğuz, Arzu and Akyıldız, Arif and Hendem, Engin and Almuradova, Elvina and Altundağ, Özden and Altundağ, Kadri},
  title = {Real-World Outcomes of Neoadjuvant Pembrolizumab plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer: A Multicenter Study from Türkiye},
  journal = {Eurasian Journal of Medical Investigation},
  year = {2026},
  pages = {171--178},
  doi = {10.14744/ejmi.266171}
}
Kostenlos starten →